Pharmacokinetics and pharmacodynamics of intravenous and oral (S)‐ketamine: Investigating metabolite contribution to subjective effects
British Journal of Clinical Pharmacology · 2026-07 · 92 (7) · 2260-2271
DOI: 10.1002/bcp.70503 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 06.03.2026. Verfasst von Marije E Otto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human Drug Research (CHDR), Leiden, the Netherlands. Hauptthemen laut MEDLINE: Antidepressive Agents, Ketamine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Centre for Human Drug Research.
Abstract (Originalsprache)
Aims
Oral administration of (S)‐ketamine for treatment‐resistant depression (TRD), as alternative to the registered intranasal or off‐label intravenous administrations, has high potential. However, it is characterized by an extensive first‐pass metabolism, resulting in low (S)‐ketamine exposure and high levels of active metabolites, including (S)‐norketamine and (S)‐hydroxynorketamine. The relative contribution of the parent and metabolites to the resulting antidepressant effects remains unclear. Therefore, this study aimed to first characterize the pharmacokinetics (PK) of (S)‐ketamine and its metabolites after oral and intravenous administration in healthy participants and secondly quantify the pharmacokinetic/pharmacodynamic (PKPD) relationship of (S)‐ketamine and (S)‐norketamine to the subjective effects measured on the visual analogue scale (VAS) ‘Feeling High’.
Methods
Data from a previously conducted clinical study was used, where 17 healthy participants received oral (0.20 and 0.45 mg/kg) and intravenous (0.4 mg/kg over 40 min) (S)‐ketamine in a randomized, placebo‐controlled, crossover clinical trial. A semi‐physiological population PK model was developed to describe the first‐pass metabolism and (S)‐ketamine and subsequently (S)‐norketamine concentrations were linked to the VAS ‘Feeling High’ using a bounded integer modelling approach.
Results
A significant (S)‐norketamine PKPD relationship was determined alongside (S)‐ketamine, but estimated variance of the bounded integer model was high warranting further investigation.
Conclusions
Our analysis suggests that not (S)‐ketamine, but its metabolite, is the main driver of subjective effects after oral administration, and as such may also contribute to antidepressant effects in TRD patients receiving oral (S)‐ketamine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Human Drug Research (CHDR), Leiden, the Netherlands.
- Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, the Netherlands.
- Leiden University Medical Centre (LUMC), Leiden, the Netherlands.
ORCID-Profile: Marije E Otto, Joost C van Mechelen, Laura G J M Borghans
Förderung
- Centre for Human Drug Research
Zitieren
APA
Otto, M. E., Jacobs, G. E., van Mechelen, J. C., Borghans, L. G. J. M., van Hasselt, J. G. C., & Aulin, L. B. S. (2026). Pharmacokinetics and pharmacodynamics of intravenous and oral (S)‐ketamine: Investigating metabolite contribution to subjective effects. British Journal of Clinical Pharmacology, 92(7), 2260-2271. https://doi.org/10.1002/bcp.70503
Vancouver
Otto ME, Jacobs GE, van Mechelen JC, Borghans LGJM, van Hasselt JGC, Aulin LBS. Pharmacokinetics and pharmacodynamics of intravenous and oral (S)‐ketamine: Investigating metabolite contribution to subjective effects. British Journal of Clinical Pharmacology. 2026;92(7):2260-2271. doi:10.1002/bcp.70503
BibTeX
@article{Otto2026,
author = {Otto, Marije E and Jacobs, Gabriël E and van Mechelen, Joost C and Borghans, Laura G J M and van Hasselt, Johan G C and Aulin, Linda B S},
title = {Pharmacokinetics and pharmacodynamics of intravenous and oral (S)‐ketamine: Investigating metabolite contribution to subjective effects},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
volume = {92},
number = {7},
pages = {2260--2271},
doi = {10.1002/bcp.70503}
}
EUVIMED